Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates-new perspectives for folate receptor-targeted radionuclide therapy.

Patrycja GuzikMartina BenešováMagdalena RatzJosep M Monné RodríguezLuisa M DeberleRoger SchibliCristina Müller

Published in: European journal of nuclear medicine and molecular imaging (2020)

This study demonstrated the promising potential of 5-MTHF-based radioconjugates for FR-targeting. Application of [177Lu]Lu-6R-RedFol-1 resulted in unprecedentedly high tumor-to-kidney ratios and, as a consequence, a superior therapeutic effect as compared with [177Lu]Lu-OxFol-1. These findings, together with the absence of early side effects, make [177Lu]Lu-6R-RedFol-1 attractive in view of a future clinical translation.

Keyphrases

cancer therapy
drug delivery
risk assessment
cell therapy
climate change
human health